 NOTE: Patients with Ph ALL received imatinib 340 mgm2 PO maximum 600 mg daily starting day 18 in combination with HR chemotherapy until they proceeded to stem cell transplant. Patients with Ph ALL patients did not participate in asparaginase randomization but were directly assigned to receive IM-EC during post-induction therapy. 